Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.

× No keyword cloud information.

9 in total

1. Cutting the Cost of Health Care: The Physician's Role.

Authors: Herbert L Fred
Journal: Tex Heart Inst J Date: 2016-02-01

2. Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans.

Authors: Dhruv S Kazi; Christine Y Lu; Grace A Lin; Colette DeJong; R Adams Dudley; Randi Chen; Chien-Wen Tseng
Journal: JAMA Cardiol Date: 2017-10-01 Impact factor: 14.676

3. Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy.

Authors: Benjamin Chin-Yee; S V Subramanian; Amol A Verma; Andreas Laupacis; Fahad Razak
Journal: Milbank Q Date: 2018-06 Impact factor: 4.911

4. The Core Value of Cost-Effectiveness Analyses.

Authors: Sanket S Dhruva; Harlan M Krumholz
Journal: J Am Coll Cardiol Date: 2016-01-05 Impact factor: 24.094

5. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.

Authors: Alejandro Arrieta; Timothy F Page; Emir Veledar; Khurram Nasir
Journal: PLoS One Date: 2017-01-12 Impact factor: 3.240

6. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.

Authors: Usha G Mallya; Susan H Boklage; Andrew Koren; Thomas E Delea; C Daniel Mullins
Journal: Pharmacoeconomics Date: 2018-01 Impact factor: 4.981

7. Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study.

Authors: Dennis T Ko; Anam M Khan; Gynter Kotrri; Peter C Austin; Harindra C Wijeysundera; Maria Koh; Anna Chu; Cynthia A Jackevicius; Patrick R Lawler; Jack V Tu
Journal: J Am Heart Assoc Date: 2018-11-06 Impact factor: 5.501

Review 8. Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?

Authors: Andy Eunwoo Kim; David Hohyun Choi; Jongwha Chang; Sean Hyungwoo Kim
Journal: Clin Drug Investig Date: 2020-10-09 Impact factor: 2.859

Review 9. PCSK9 inhibitors in the prevention of cardiovascular disease.

Authors: James Latimer; Jonathan A Batty; R Dermot G Neely; Vijay Kunadian
Journal: J Thromb Thrombolysis Date: 2016-10 Impact factor: 2.300

9 in total